Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125729 · ClinicalTrials.gov registry record · NA
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
A NA study of Stage IV Colorectal Cancer AJCC v8 and Stage III Colorectal Cancer AJCC v8, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 13
- Study locations
NCT07125729 is a NA study of Stage IV Colorectal Cancer AJCC v8 and Stage III Colorectal Cancer AJCC v8 that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 150 participants, above the 102-participant average among 22 other Stage IV Colorectal Cancer AJCC v8 trials with a reported enrollment target (47% higher). The trial reports 13 study locations across 4 states.
The verdict
NCT07125729, a NA study of Stage IV Colorectal Cancer AJCC v8 and Stage III Colorectal Cancer AJCC v8, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 13
- Study locations
Study Summary
This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery (resectable). MRD testing looks for evidence of remaining tumor following treatment that is only apparent using highly sensitive techniques. There are few effective tools available outside of imaging to identify CRC patients with MRD who may be at the highest risk for cancer recurrence after surgery. Early detection of CRC recurrence after surgery is important, as it may increase the chance of curative (ability to cure) outcomes for patients with cancer recurrence. Currently, the Signatera assay is used to monitor whether CRC recurs after surgery, however it is not a very sensitive test. Early work with the Haystack assay suggests it may be more sensitive than the Signatera assay, which may be more effective for the early detection of cancer recurrence in patients with resectable stage II-IV CRC.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
- OTHER cfDNA or ctDNA Measurement
Study Locations (13)
California
- City of Hope Corona - Corona
- City of Hope Comprehensive Cancer Center - Duarte
- City of Hope Seacliff - Huntington Beach
- City of Hope at Irvine Lennar - Irvine
- City of Hope Antelope Valley - Lancaster
- City of Hope at Long Beach Elm - Long Beach
- City of Hope at Newport Beach Fashion Island - Newport Beach
- City of Hope South Pasadena - South Pasadena
- City of Hope South Bay - Torrance
- City of Hope Upland - Upland
Arizona
- CTCA at Western Regional Medical Center - Goodyear
Georgia
- City of Hope Atlanta Cancer Center - Newnan
Illinois
- City of Hope at Chicago - Zion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-12 |
| Est. Completion | 2028-01-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07125729
The ClinicalTrials.gov registry entry for NCT07125729 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 22 other Stage IV Colorectal Cancer AJCC v8 trials with a reported enrollment target (47% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage IV Colorectal Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT07125729 reports 13 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Georgia.
Frequently Asked Questions
What is clinical trial NCT07125729 about?
NCT07125729 is a clinical study titled "Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients". This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery (resectable). MRD t...
What is the current status of trial NCT07125729?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-07-12. Estimated completion is 2028-01-09.
What conditions does trial NCT07125729 study?
This clinical trial studies the following conditions: Stage IV Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Resectable Colorectal Carcinoma.
What interventions are being tested in trial NCT07125729?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER), cfDNA or ctDNA Measurement (OTHER).
Who is sponsoring clinical trial NCT07125729?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07125729 being conducted?
This trial has 13 study locations across Arizona, California, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Colorectal Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
RECRUITING · NA
-
Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer
ACTIVE NOT RECRUITING · NA
-
Diet Education Program for Stage I-IV Colorectal Cancer Survivors
COMPLETED · NA
-
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
RECRUITING · Phase 1
-
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
RECRUITING · Phase 1
-
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Stage IV Colorectal Cancer AJCC v8
All registered trials for this condition
Stage III Colorectal Cancer AJCC v8
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.